Librela for Pets

Librela contains bedinvetmab, a monoclonal antibody used to control pain associated with osteoarthritis in dogs. It works by binding to nerve growth factor (NGF), a protein involved in pain signaling, which can help improve comfort and mobility in dogs with arthritis. In U.S. studies reviewed by the FDA, the weight of evidence supported effectiveness when at least two doses were given 28 days apart. Librela is not a general pain medication for every cause of limping or stiffness, so your veterinarian should confirm that osteoarthritis is the problem before prescribing it.

• Commonly reported side effects in studies included increased blood urea nitrogen (BUN), urinary tract infection, bacterial skin infection, dermatitis or rash, injection-site discomfort, vomiting, and reduced appetite or weight loss.
• Post-approval reports have also included lethargy, diarrhea, increased thirst, increased urination, urinary incontinence, muscle weakness, muscle tremors, lameness, recumbency, ataxia, seizures, and other neurologic signs.
• Some dogs had serious outcomes reported after use, including euthanasia or death, although post-approval reports do not always prove the medication caused the event.
• Call your vet promptly if your dog seems weaker than usual, develops balance problems, new urinary accidents, persistent vomiting or diarrhea, or any sudden neurologic change.

Librela is given as a monthly injection under the skin by a veterinarian. Follow your vet's instructions and keep all scheduled recheck appointments. Because dogs may feel better quickly, ask your veterinarian how to return to activity gradually so your dog does not overdo exercise and risk injury. Your vet may recommend monitoring such as exams, bloodwork, or urinalysis during treatment, especially for dogs with other health conditions or if side effects develop. If your dog misses an appointment, contact your veterinary team to reschedule rather than trying to adjust treatment on your own.